Navigation Links
Chronic Use of Prescription Painkillers Continues Following Bariatric Surgery

DENVER, Oct. 1, 2013 /PRNewswire/ -- Chronic use of prescription painkillers, also known as opioids, among obese patients prior to bariatric surgery continues after surgery, according to a new Kaiser Permanente study published today in the Journal of the American Medical Association.


Researchers examined the electronic medical records of 11,719 obese patients who underwent bariatric surgery between 2005-2009 at one of 10 U.S. sites in the Scalable Partnering Network. Participating patients were evaluated one year before and one year after surgery. Seventy-seven percent of the obese patients who exhibited chronic opioid use prior to surgery continued to use these medications chronically one year after their procedure. Chronic opioid use among these patients also increased by 13 percent the first year after surgery.

"Obese patients are often more sensitive to pain and tend to be prescribed increasing opioid doses in order to manage that pain," said lead study author Marsha A. Raebel, PharmD, a senior investigator at Kaiser Permanente's Institute for Health Research.

In the year prior to their surgical procedures, 56 percent of the patients in this study reported no opioid use for pain management, 36 percent used some opioids and 8 percent used opioids on a chronic basis. Chronic opioid use was defined as having 10 or more prescriptions over at least 90 days or at least a 120-day total supply of medication sometime in the year prior to surgery. Some opioid use was defined as one to nine prescriptions over 90 days or less than a 120-day supply.

"There are limited options for pain management available to bariatric surgery patients because non-steroidal, anti-inflammatory medications increase the risk of ulcers, particularly after bariatric surgery," said Dr. Raebel. "Given the increasing chronic usage rate reported in this study, it's clear that the medical community needs to develop better pain management programs for patients who use opioids long-term following bariatric surgery."

More than 200,000 bariatric surgeries were performed in the U.S. in 2012 and prescription painkiller usage has exploded at the same time. According to the medical journal Pain, 4.3 million adults use opioid medications on a regular basis. The most commonly used prescription opioids are hydrocodone, oxycodone and morphine. Long-term opioid use can lead to many health issues, the most serious being addiction and fatal overdoses.

Kaiser Permanente is committed to furthering understanding of chronic opioid use. Earlier in 2013, a Kaiser Permanente study found that regularly taking opioids increases a man's risk of erectile dysfunction.

Kaiser Permanente can conduct transformational health research like this in part because it has the largest private patient-centered electronic health record system in the world. The organization's electronic health record system, Kaiser Permanente HealthConnect®, securely connects 9.1 million patients to 17,000 physicians in 611 medical offices and 37 hospitals. It also connects Kaiser Permanente's research scientists to one of the most extensive collections of longitudinal medical data available, facilitating studies and important medical discoveries that shape the future of health care delivery for patients and the medical community.

Additional study authors include: Sophia R. Newcomer, MPH, Liza M. Reifler, MPH, and Elizabeth A. Bayliss, MD, MSPH, of the Kaiser Permanente Institute for Health Research; Denise Boudreau, PhD, of Group Health Research Institute, Seattle; Thomas E. Elliott, MD, of the Essentia Institute of Rural Health, Duluth, Minn.; Lynn DeBar, PhD, of the Kaiser Permanente Center for Health Research, Portland, Ore.; Ameena Ahmed, MD, MPH, and David Fisher, MD, of the Permanente Medical Group, San Francisco; Pamala A. Pawloski, PharmD, of the HealthPartners Institute for Education and Research, Minneapolis; and W. Troy Donahoo, MD, of the Colorado Permanente Medical Group, Denver.

About the Kaiser Permanente Colorado Institute for Health Research
The Kaiser Permanente Colorado Institute for Health Research (IHR) publishes and disseminates epidemiologic, behavioral, and health services research to improve the health and medical care of Kaiser Permanente members and the communities it serves. The organization has a specific focus on conducting research that can be translated into clinical practice, health promotion, and policies to influence the health of individuals and populations. Currently, the IHR's staff of more than 120 is working on more than 160 epidemiological, clinical, behavioral, community, and health services research projects. Now in its 20th year of operation, the IHR is responsible for many landmark findings. Among the most notable are recent studies about vaccine safety and refusal, and home blood-pressure monitoring and research that identified life-saving practices for heart attack patients in the emergency room. Teams of investigators collaborate on major research projects with national partners including the Centers for Disease Control and Prevention Vaccine Safety Datalink, the HMO Research Network, and the NIH Cardiovascular Research Network and the Cancer Research Network. Learn more at

About Kaiser Permanente

Kaiser Permanente is committed to helping shape the future of health care. We are recognized as one of America's leading health care providers and not-for-profit health plans. Founded in 1945, our mission is to provide high-quality, affordable health care services and to improve the health of our members and the communities we serve. We currently serve more than 9.1 million members in eight states and the District of Columbia. Care for members and patients is focused on their total health and guided by their personal physicians, specialists and team of caregivers. Our expert and caring medical teams are empowered and supported by industry-leading technology advances and tools for health promotion, disease prevention, state-of-the-art care delivery and world-class chronic disease management. Kaiser Permanente is dedicated to care innovations, clinical research, health education and the support of community health. For more information, go to:

For more information, contact:
Rowena Sara,, 415.318.4376
Amy Whited,, 303.344.7518

SOURCE Kaiser Permanente
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Bayers Investigational Drug Riociguat Granted FDA Orphan Drug Designation for Treatment of Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension
2. Aptel Research Launches Unique Patient-centric Syndicated Report Series That Analyze the Patient Journey for Chronic Diseases in Specialty Markets
3. arGEN-X Identifies Potent Antibody Antagonists against Complex Chronic Pain Target Nav1.7
4. Olodaterol Shows Sustained Improvements in Lung Function in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
5. Newly-Published Study Concludes Stretta May Be More Desirable GERD Treatment than Chronic PPI Use or Anti-Reflux Surgery in Some Patients
6. SanBio Announces The Completion Of Enrollment Of Its Clinical Trial Of Cell Therapy For Chronic Stroke Deficits
7. Final Patient Completes Prosonix Phase 2 Clinical Study with PSX1002 in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
8. Chronic Obstructive Pulmonary Disease (COPD) Market to 2019 - Highly-Priced New Combination Products Forecast to Capture Significant Market Share and Drive Growth
9. Abuse-Deterrent Formulations of Purdues OxyContin and Endo Pharmaceuticals Opana ER Have Not Increased PCPs Comfort When Prescribing These Products for Chronic Pain
10. After Reviewing Brief Product Profiles, Surveyed Physicians Believe that Likely Candidates for Late-Phase Chronic Kidney Disease Products from AbbVie, Mitsubishi Tanabe, Eli Lilly, Concert, Fibrogen and Pfizer are Typically Stage 3b and 4 Patients
11. Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine
Post Your Comments:
(Date:12/1/2015)... Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel ... the company will present at the LD Micro Main Event. ... Sunset Boulevard Hotel in Los Angeles, CA. ... present on Thursday, December 3, at 9:00 am Pacific time ... at least 10 minutes prior to the start of the ...
(Date:12/1/2015)... Dec. 1, 2015   MabVax Therapeutics Holdings, Inc ... announces it has filed an Investigational New Drug Application ... for the Company,s lead fully human antibody product HuMab ... MabVax plans to initiate the Phase I clinical trial ... --> The planned Phase I trial will ...
(Date:12/1/2015)... 2015   Craneware, Inc ., the healthcare ... announced the company will showcase a new version ... solution at the American Society for Health-System ... The new features are focused on simplifying and ... managing enterprise-wide pharmacy charges to ensure compliance and ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... 2015 , ... Speech and physical therapies are traditionally conducted ... and under the right circumstances, these practices can be merged. This combination ... his or her therapeutic sessions, as well as gives the physical and speech ...
(Date:12/1/2015)... Wayland, MA (PRWEB) , ... December 01, 2015 , ... ... adults has a tattoo — a number even greater among Millennials (a whopping one ... there are more and more people who are dissatisfied with their ink. In fact, ...
(Date:12/1/2015)... Libertyville, IL (PRWEB) , ... December 01, 2015 ... ... catheters, keeping their independence is everything. That is why Hollister Incorporated has launched ... excited to offer this next product in the VaPro touch free catheter portfolio,” ...
(Date:12/1/2015)... ... December 01, 2015 , ... Lutronic, a leading innovator of ... latest addition to the devices for sale in the United States. Clarity is ... long-pulsed 1064 nm Nd:YAG lasers, into a single platform that is easy to own ...
(Date:12/1/2015)... , ... December 01, 2015 , ... With FCPX ... and with full control over customization, the possibilities are truly endless, all with a ... randomization, overlay depth position, vertical flip, horizontal flip, depth of field and more, all ...
Breaking Medicine News(10 mins):